

Alan M Rapoport

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5416433/publications.pdf>

Version: 2024-02-01

62
papers

2,866
citations

218677

26
h-index

168389

53
g-index

63
all docs

63
docs citations

63
times ranked

1732
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurobiology of migraine progression. <i>Neurobiology of Pain (Cambridge, Mass)</i> , 2022, 12, 100094.	2.5	14
2	The Evolution of Medication Overuse Headache: History, Pathophysiology and Clinical Update. <i>CNS Drugs</i> , 2021, 35, 545-565.	5.9	25
3	Potassium channel openers – novel triggers of aura and migraine. <i>Nature Reviews Neurology</i> , 2021, 17, 397-398.	10.1	5
4	Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine. <i>Headache</i> , 2020, 60, 229-234.	3.9	14
5	Acute Care and Treatment of Migraine. <i>Journal of Neuro-Ophthalmology</i> , 2020, 40, 472-484.	0.8	7
6	Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications. <i>Journal of Headache and Pain</i> , 2019, 20, 83.	6.0	37
7	Some aspects on the pathophysiology of migraine and a review of device therapies for migraine and cluster headache. <i>Neurological Sciences</i> , 2019, 40, 75-80.	1.9	9
8	Migraine and episodic Vertigo: a cohort survey study of their relationship. <i>Journal of Headache and Pain</i> , 2019, 20, 33.	6.0	23
9	Device profile of the Nerivio [®] for acute migraine treatment: overview of its efficacy and safety. <i>Expert Review of Medical Devices</i> , 2019, 16, 1017-1023.	2.8	16
10	The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment. <i>Headache</i> , 2019, 59, 383-393.	3.9	32
11	The Headache Cooperative of New England (HCNE) Symposium on Calcitonin Gene-Related Peptide. <i>Headache</i> , 2018, 58, 217-217.	3.9	0
12	A new era in headache treatment. <i>Neurological Sciences</i> , 2018, 39, 47-58.	1.9	13
13	DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study. <i>Headache</i> , 2018, 58, 676-687.	3.9	31
14	Scent of aura? Clinical features of olfactory hallucinations during a migraine attack (OHM). <i>Cephalalgia</i> , 2017, 37, 154-160.	3.9	10
15	A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. <i>Journal of Headache and Pain</i> , 2017, 18, 31.	6.0	17
16	Diclofenac potassium for oral solution (CAMBIA [®]) in the acute management of a migraine attack: clinical evidence and practical experience. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 217-226.	3.5	7
17	New strategies for the treatment and prevention of primary headache disorders. <i>Nature Reviews Neurology</i> , 2016, 12, 635-650.	10.1	83
18	Update on the Pharmacological Treatment of Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2016, 20, 6.	2.9	32

#	ARTICLE	IF	CITATIONS
19	Emerging treatments for the primary headache disorders. <i>Neurological Sciences</i> , 2015, 36, 109-113.	1.9	14
20	The iontophoretic transdermal system formulation of sumatriptan as a new option in the acute treatment of migraine: a perspective. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 160-165.	3.5	3
21	Commentary on Westergaard's "Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: A systematic review". <i>Cephalalgia</i> , 2015, 35, 637-638.	3.9	0
22	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. <i>Lancet Neurology</i> , The, 2015, 14, 1091-1100.	10.2	221
23	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. <i>Lancet Neurology</i> , The, 2015, 14, 1081-1090.	10.2	236
24	Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. <i>Pain Management</i> , 2014, 4, 123-128.	1.5	9
25	New treatments for headache. <i>Neurological Sciences</i> , 2014, 35, 89-97.	1.9	13
26	The Pipeline in Headache Therapy. <i>CNS Drugs</i> , 2013, 27, 717-729.	5.9	16
27	Update on future headache treatments. <i>Neurological Sciences</i> , 2013, 34, 101-108.	1.9	5
28	Calcitonin Gene-Related Peptide (CGRP) and Migraine Current Understanding and State of Development. <i>Headache</i> , 2013, 53, 1230-1244.	3.9	128
29	Sumatriptan transdermal iontophoretic patch (NP101-Zelrix®): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 429.	2.2	23
30	Acute Treatment of Migraine: Established and Emerging Therapies. <i>Headache</i> , 2012, 52, 60-64.	3.9	8
31	The therapeutic future in headache. <i>Neurological Sciences</i> , 2012, 33, 119-125.	1.9	23
32	The Association of Obesity With Episodic and Chronic Migraine. <i>Headache</i> , 2012, 52, 663-671.	3.9	29
33	What Happens to the Old Headache Medicines?. <i>Headache</i> , 2012, 52, 701-706.	3.9	11
34	Obesity and Chronic Daily Headache. <i>Current Pain and Headache Reports</i> , 2012, 16, 101-109.	2.9	33
35	The Authors' Reply. <i>CNS Drugs</i> , 2011, 25, 171-173.	5.9	1
36	New drug delivery options for migraine. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 771-773.	2.8	4

#	ARTICLE	IF	CITATIONS
37	New acute treatments for headache. <i>Neurological Sciences</i> , 2010, 31, 129-132.	1.9	15
38	Obesity and Migraine: The Effect of Age, Gender and Adipose Tissue Distribution. <i>Headache</i> , 2010, 50, 52-62.	3.9	130
39	Acute and preventive treatment of cluster headache and other trigeminal autonomic cephalgias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2010, 97, 431-442.	1.8	8
40	Role of Antiepileptic Drugs as Preventive Agents for Migraine. <i>CNS Drugs</i> , 2010, 24, 21-33.	5.9	39
41	Triptans for the Management of Migraine. <i>Drugs</i> , 2010, 70, 1505-1518.	10.9	110
42	Innovative Delivery Systems for Migraine. <i>CNS Drugs</i> , 2010, 24, 929-940.	5.9	46
43	Acute treatment of migraine headache. <i>Techniques in Regional Anesthesia and Pain Management</i> , 2009, 13, 9-15.	0.2	8
44	Acute and prophylactic treatments for migraine: present and future. <i>Neurological Sciences</i> , 2008, 29, 110-122.	1.9	16
45	Memantine in the Preventive Treatment of Refractory Migraine. <i>Headache</i> , 2008, 48, 1337-1342.	3.9	88
46	Medication Overuse Headache. <i>CNS Drugs</i> , 2008, 22, 995-1004.	5.9	28
47	Satisfaction With Current Migraine Therapy: Experience From 3 Centers in US and Sweden. <i>Headache</i> , 2007, 47, 475-479.	3.9	82
48	The Impact of Topiramate on Health-Related Quality of Life Indicators in Chronic Migraine. <i>Headache</i> , 2007, 47, 1398-1408.	3.9	57
49	Medications Associated with Probable Medication Overuse Headache Reported in a Tertiary Care Headache Center Over a 15-Year Period. <i>CME. Headache</i> , 2006, 46, 766-772.	3.9	118
50	Naratriptan in the Preventive Treatment of Refractory Transformed Migraine: A Prospective Pilot Study. <i>Headache</i> , 2005, 45, 1400-1406.	3.9	15
51	Levetiracetam in the preventive treatment of transformed migraine: A prospective, open-label, pilot study. <i>Current Therapeutic Research</i> , 2005, 66, 212-221.	1.2	26
52	Prophylactic migraine therapy: Emerging treatment options. <i>Current Pain and Headache Reports</i> , 2004, 8, 178-184.	2.9	21
53	Intranasal Medications for the Treatment of Migraine and Cluster Headache. <i>CNS Drugs</i> , 2004, 18, 671-685.	5.9	62
54	Naratriptan in the Preventive Treatment of Refractory Chronic Migraine: A Review of 27 Cases. <i>Headache</i> , 2003, 43, 482-489.	3.9	27

#	ARTICLE	IF	CITATIONS
55	The Triptan Formulations. <i>CNS Drugs</i> , 2003, 17, 431-447.	5.9	74
56	New developments in migraine prophylaxis. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 433-443.	1.8	13
57	Intranasal Civamide for the Treatment of Episodic Cluster Headaches. <i>Archives of Neurology</i> , 2002, 59, 990.	4.5	110
58	Frovatriptan: Pharmacological Differences and Clinical Results. <i>Current Medical Research and Opinion</i> , 2001, 17, s68-70.	1.9	3
59	Efficacy of Gabapentin in Migraine Prophylaxis. <i>Headache</i> , 2001, 41, 119-128.	3.9	317
60	Triptans Are All Different. <i>Archives of Neurology</i> , 2001, 58, 1479.	4.5	39
61	Analgesic Rebound Headache in Clinical Practice: Data From a Physician Survey. <i>Headache</i> , 1996, 36, 14-19.	3.9	143
62	Analgesic Rebound Headache. <i>Headache</i> , 1988, 28, 662-665.	3.9	119